The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors
Author:
Affiliation:
1. Department of Pediatrics Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta, Emory University School of Medicine Atlanta GA USA
2. Section of Hematology/Oncology Tulane University School of Medicine New Orleans LA USA
Funder
HEMA Biologics, LLC
Publisher
Wiley
Subject
Genetics (clinical),Hematology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13845
Reference60 articles.
1. FEIBA versus NovoSeven in Hemophilia Patients with Inhibitors
2. Genentech.Emicizumab‐kxwh safety information.https://www.emicizumabinfo.com/hcp/emicizumab-safety-information.html. Accessed May 7 2019.
3. FeketeLF HolstSL PeetoomF De VeberLI."Auto"‐factor IX concentrate: A new therapeutic approach to treatment of hemophilia A patients with inhibitors [Abstract]. 14th International Congress of Hematology. San Paulo;1972.https://ci.nii.ac.jp/naid/10006804560/en/. Accessed March 13 2019.
4. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.
5. Therapeutic choices for patients with hemophilia and high-titer inhibitors
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders;Annals of Hematology;2023-06-30
2. Congenital Factor VII Deficiency, Diagnosis, and Management;Congenital Bleeding Disorders;2023
3. Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug;CPT: Pharmacometrics & Systems Pharmacology;2022-10-18
4. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors;Haemophilia;2022-04-27
5. Infusão endovenosa domiciliar: tecnologias educativas para o cuidado à pessoa com hemofilia;Acta Paulista de Enfermagem;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3